Prota Therapeutics

Developing a novel approach to allergen immunotherapy - providing long lasting peace of mind to food allergy sufferers

Visit Website

Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel oral immunotherapy treatments. Prota holds an exclusive license to the proprietary food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15m was secured from OneVentures, a leading Australian venture capital investment firm (OneVentures’ Healthcare Fund III) – including $5M from the Australian Commonwealth Government Biomedical Translation Fund – as well as private investment. This has enabled Prota to advance it’s clinical program, develop scalable cGMP product manufacturing processes, and initiate discussions with regulatory agencies in the lead up to a planned large-scale pivotal Phase 3 efficacy and safety study for the PRT120 peanut allergy treatment.

Prota Therapeutics has its headquarters in Melbourne, Australia.

Employment Hero
15 April 2022
20 April 2022
decor decor decor
decor decor decor decor decor